Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

Published:2018 Issue:12 Volume:41 Page:755-761
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Aguiar-Bujanda David,Dueñas-Comino Arancha,Saura-Grau Salvador,Ros-Sanjuan Laura,Blanco-Sanchez Maria J.,Hernandez-Sosa Maria,Mori-De Santiago Marta,Galvan-Ruiz Saray,Lorenzo-Barreto Jose E.,Vargas-Prado Ana M.,Bohn-Sarmiento Uriel

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.

2. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.

3. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.

4. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.

5. Zhou C, Wu YL, Chen G, et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilizing Macrophages Missile for Sulfate-Based Nanomedicine Delivery in Lung Cancer Therapy;Research;2024-01

2. Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma;British Journal of Cancer;2023-04-29

3. Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer;Journal of Cancer Research and Therapeutics;2023-04-06

4. Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes;Scientific Reports;2022-03-24

5. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor;Translational Oncology;2022-03